Trial Profile
Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin Lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Jan 2024
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Dacarbazine; Doxorubicin; Vinblastine
- Indications Hodgkin's disease
- Focus Therapeutic Use
- Acronyms NIVAHL
- 12 Dec 2023 Results (n=87) assessing impact on pregnancies and gonadal function in patients treated with with Nivolumab-AVD, presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Dec 2023 Results assessing preplanned Patient reported outcomes; analysis of quality of life (QoL), fatigue and life situation of HL patients presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Sep 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.